Boston Scientific Corporation $BSX Position Raised by Nissay Asset Management Corp Japan ADV

Key Points

• Nissay Asset Management Corp Japan ADV increased its stake in Boston Scientific Corporation by 1.3%, owning 183,108 shares valued at approximately $18.47 million.
• Insider activity saw EVP Arthur C. Butcher selling 17,313 shares, representing a 42.32% decrease in his ownership, while Director Yoshiaki Fujimori sold 2,901 shares, reflecting a 58.23% drop in his position.
• Boston Scientific reported quarterly earnings of $0.75 per share, beating estimates and showing a 22.8% year-over-year revenue increase to $5.06 billion.

Nissay Asset Management Corp Japan ADV raised its position in Boston Scientific Corporation (NYSE:BSX - Free Report) by 1.3% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 183,108 shares of the medical equipment provider's stock after acquiring an additional 2,380 shares during the quarter. Nissay Asset Management Corp Japan ADV's holdings in Boston Scientific were worth $18,472,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the company. Vanguard Group Inc. grew its position in Boston Scientific by 1.3% in the first quarter. Vanguard Group Inc. now owns 134,588,729 shares of the medical equipment provider's stock valued at $13,577,311,000 after acquiring an additional 1,697,945 shares in the last quarter. Invesco Ltd. boosted its stake in shares of Boston Scientific by 5.3% during the 1st quarter. Invesco Ltd. now owns 16,624,940 shares of the medical equipment provider's stock valued at $1,677,124,000 after buying an additional 834,274 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of Boston Scientific by 10.8% during the 1st quarter. Goldman Sachs Group Inc. now owns 14,143,332 shares of the medical equipment provider's stock valued at $1,426,779,000 after buying an additional 1,383,524 shares during the last quarter. Amundi boosted its stake in shares of Boston Scientific by 2.6% during the 1st quarter. Amundi now owns 12,308,715 shares of the medical equipment provider's stock valued at $1,212,408,000 after buying an additional 311,034 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Boston Scientific by 18.7% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 10,839,362 shares of the medical equipment provider's stock valued at $968,172,000 after buying an additional 1,709,461 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company's stock.

Boston Scientific Stock Performance

BSX traded up $0.92 during trading hours on Monday, hitting $108.14. 7,454,396 shares of the stock were exchanged, compared to its average volume of 5,736,611. The stock has a 50-day simple moving average of $104.78 and a 200-day simple moving average of $102.18. Boston Scientific Corporation has a 12 month low of $80.64 and a 12 month high of $108.94. The stock has a market cap of $160.23 billion, a price-to-earnings ratio of 64.37, a price-to-earnings-growth ratio of 2.58 and a beta of 0.65. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The firm had revenue of $5.06 billion for the quarter, compared to analysts' expectations of $4.89 billion. During the same period last year, the business posted $0.62 earnings per share. The firm's revenue for the quarter was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. Leerink Partners assumed coverage on Boston Scientific in a research note on Monday, June 16th. They set an "outperform" rating and a $118.00 target price for the company. Needham & Company LLC reiterated a "buy" rating and set a $115.00 target price on shares of Boston Scientific in a research note on Wednesday, May 28th. Barclays increased their target price on Boston Scientific from $125.00 to $133.00 and gave the company an "overweight" rating in a research note on Thursday, July 24th. Wells Fargo & Company increased their target price on Boston Scientific from $118.00 to $124.00 and gave the company an "overweight" rating in a research note on Thursday, July 24th. Finally, Morgan Stanley increased their target price on Boston Scientific from $120.00 to $125.00 and gave the company an "overweight" rating in a research note on Friday, May 16th. Three analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $117.79.

Insider Buying and Selling

In other Boston Scientific news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the firm's stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $105.43, for a total value of $5,271,500.00. Following the sale, the executive vice president directly owned 178,342 shares in the company, valued at approximately $18,802,597.06. This trade represents a 21.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Arthur C. Butcher sold 17,313 shares of the firm's stock in a transaction on Friday, August 1st. The shares were sold at an average price of $104.63, for a total value of $1,811,459.19. Following the completion of the sale, the executive vice president owned 23,600 shares in the company, valued at $2,469,268. The trade was a 42.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 174,214 shares of company stock valued at $18,397,457. 0.50% of the stock is owned by corporate insiders.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.